Uniqure N.V. QURE

$23.87 +0.90 (3.92%)

Valuation

Market cap
1,593,337,000
Revenue TTM
$16,100,000
Net income TTM
$-198,970,000
P/E (trailing)
0.00
P/E (forward)
—
Profit margin
-1,235.84%
Debt to equity
0.15

Trading

Volume
1,838,900
Avg volume
2,390,520
Day's range
$22.86 – $24.09
Shares out
69,366,000
Stochastic %K
47%
Beta
1.14
Analysts
Strong Buy
Price target
$58.08

Price

Company profile

uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases in the United States. The company offers HEMGENIX that allows people living with hemophilia B to produce factor IX, which can lower the risk of bleeding. Its lead product candidate is AMT-130, a gene therapy candidate, which is in Phase I/II clinical study for the treatment of Huntington's disease. The company also develo...

Show more

uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases in the United States. The company offers HEMGENIX that allows people living with hemophilia B to produce factor IX, which can lower the risk of bleeding. Its lead product candidate is AMT-130, a gene therapy candidate, which is in Phase I/II clinical study for the treatment of Huntington's disease. The company also develops AMT-260, which is in Phase I/IIa clinical trial for the treatment of mesial temporal lobe epilepsy; AMT-162, which is in Phase I/IIa clinical trial to treat superoxide dismutase enzyme-amyotrophic lateral sclerosis; and AMT-191, an investigational gene therapy candidate which is in phase I/IIa clinical trial for the treatment of fabry disease. It has a licensing agreement with Apic Bio to develop, manufacture, and commercialize intrathecally administered investigational gene therapy for ALS caused by mutations in SOD-1; and development and commercial supply agreement with CLS Bhering. uniQure N.V. was founded in 1998 and is headquartered in Amsterdam, the Netherlands.

Industry
Biotechnology
Sector
Healthcare
Phone
31 20 240 6000
Website
https://www.uniqure.com
Address
Paasheuvelweg 25, Amsterdam, Netherlands

Latest news

Stocktwits

fda_tracker Nov 3, 5:00 PM
$QURE New PDUFA Date 2027-05-01 uniQure N.V. Link: https://www.sec.gov/Archives/edgar/data/1590560/000110465926120915/tm2628699d1_8k.htm Calendar: http://www.fdatracker.com/fda-calendar/
0 replies
Monkey7779192 Nov 3, 3:41 AM
$QURE I want an adcom but it looks like fda will cancel it and give crl then ask them to do the confimatory trial.
0 replies
BiotechCatalystCalendar Nov 3, 1:59 AM
Pharmacist's view of election season: Common side effects of watching the news may include anxiety, insomnia, and yelling at the TV. Do not mix with checking $INO or $QURE. Consult your calendar before making decisions. 📅
0 replies
BiotechCatalystCalendar Nov 2, 3:34 PM
Huntington's gene therapy just got an FDA date: May 1, 2027 📅 $QURE https://biotechcatalystcalendar.substack.com/p/catalyst-alert-qure-huntingtons-priority-review
0 replies
LibertarianTreehugger Nov 2, 2:52 PM
FDA Fast-Tracks Experimental Gene Therapy for Huntington's Disease: https://jlsfund.substack.com/p/fda-fast-tracks-experimental-gene $QURE
0 replies
kundakunda Nov 2, 2:49 PM
$QURE seems like someone is panic selling over the confirmatory trial
0 replies
BioResearcher Nov 2, 2:48 PM
$QURE Selling on good news ???
0 replies
prismmarketview Nov 2, 1:55 PM
🧬 FDA accepts $QURE ’s BLA for AMT-130, its Huntington’s gene therapy, with Priority Review. PDUFA date: May 1, 2027. If approved, it would be the first disease-modifying treatment for Huntington’s. Full story 👇 https://prismmarketview.com/uniqures-huntingtons-gene-therapy-wins-fda-acceptance-and-priority-review-setting-up-a-may-2027-decision/
0 replies